GlassScriptPhysician profile
Kristin Hunter
NPI 1275990327
$5,533.72
in general payments reported to CMS, 2019-2025
26 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $560 · 2023: $956 · 2024: $1,546 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.71 |
| Education | $102.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,467.07 | 2021-2025 | |
| Janssen Biotech, INC. | $766.42 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $588.98 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $459.28 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.66 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $328.68 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $215.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $207.92 | 2023-2025 | Epclusa |
| Ipsen Biopharmaceuticals, INC | $163.01 | 2024-2025 | Iqirvo |
| Pfizer INC. | $162.83 | 2021-2025 | |
| Ardelyx, INC. | $143.54 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $113.48 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $100.03 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $72.44 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $59.35 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $36.60 | 2025 | Cuvrior |
| Merck Sharp & Dohme LLC | $34.00 | 2021-2024 | Dificid |
| Intra-Sana Laboratories | $28.76 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $27.61 | 2022 | |
| Organon LLC | $24.50 | 2024 | |
| Novo Nordisk INC | $21.18 | 2025 | Wegovy |
| Amgen INC. | $20.01 | 2024 | |
| Celltrion USA INC. | $18.79 | 2024 | Zymfentra |
| Genzyme Corporation | $18.53 | 2024 | |
| Aimmune Therapeutics, INC. | $16.03 | 2024 | |
| Celgene Corporation | $14.88 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.